UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G/A

(Amendment No. 1)

Under the Securities Exchange Act of 1934

A.P. Pharma, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

00202J203

(CUSIP Number)

December 31, 2012

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- S Rule 13d-1(b)
- £ Rule 13d-1(c)
- £ Rule 13d-1(d)

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1745 (12-02)

^{*}The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

CUSIP No. 00202J203			13G/A	Page 2 of 2	Page 2 of 7 Pages	
1.	NAMES OF REPORTING PE I.R.S. IDENTIFICATION NO PERCEPTIVE ADVISORS	OF ABOVE I	ERSONS (ENTITIES ONLY)			
2.	CHECK THE APPROPRIATE BOX IF A GROUP* (a) £ (b) £					
3.	SEC USE ONLY					
4.	CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE, UNITED STATES OF AMERICA					
SHARES BENEFICIALLY OWNED BY FACH 5. 6. SHA		5.	SOLE VOTING POWER		0	
		6.	SHARED VOTING POWER			
		7.	SOLE DISPOSITIVE POWER		0	
	PERSON WITH:	8.	SHARED DISPOSTIVE POWER		31,504,199*	
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				31,504,199*	
10.	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) £					
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)			9.99%*		
12.	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)			IA		

CUSIP No. 00202J203			13G/A	Page 3 of 7 Pages	
13.	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) JOSEPH EDELMAN				
14.	CHECK THE APPROPRIATE BOX IF A GROUP*			(a) £ (b) £	
15.	SEC USE ONLY				
16.	CITIZENSHIP OR PLACE OF ORGANIZATION UNITED STATES OF AMERICA				
	NUMBER OF SHARES	17.	SOLE VOTING POWER		0
BENEFICIALLY OWNED BY EACH		18.	SHARED VOTING POWER	31	
		19.	19. SOLE DISPOSITIVE POWER	0	
	PERSON WITH:	20.	SHARED DISPOSTIVE POWER		31,504,199*
21.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			31,504,199*	
22.	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) £				
23.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)				
24.	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)		IN		

CUSIP No. 00202J203	1	3G/A	Page 4 of 7 Pages	
Item 1.				
(a) Name of Issuer:	A.P. Pharma, Inc.			
(b) Address of Issuer's Principal E	xecutive Offices:	123 Saginaw Drive Redwood City, CA 94	063	
Item 2.				
(a) Name of Person Filing:	defined below) of A.F	This Schedule 13G/A (the "Schedule") is being filed with respect to shares of Common Stock (as defined below) of A.P. Pharma, Inc. (the "Issuer") which are beneficially owned by Perceptive Advisors LLC and Joseph Edelman (together, the "Reporting Persons"). See Item 4 below.		
(b) Address of Principal Business	Office or, if none, Residence:	499 Park A New York,	venue, 25 th Floor NY 10022	
(c) Citizenship:	Perceptive Advisors l States Citizen.	LLC is a Delaware limited l	iability company and Joseph Edelman is a United	
(d) Title of Class of Securities:	Common Stock			
(e) CUSIP Number:	00202J203			
Item 3. If this statement is filed pur	suant to §§240.13d-1(b) or 240	.13d-2(b) or (c), check whet	her the person filing is a:	
(a) [] Broker or dealer r	egistered under section 15 of the	Act (15 U.S.C. 780).		
(b) [] Bank as defined in	n section 3(a)(6) of the Act (15 U	J.S.C. 78c).		
(c) [] Insurance compan	y as defined in section 3(a)(19)	of the Act (15 U.S.C. 78c).		
(d) [] Investment compa	(d) [] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).			
(e) [X] An investment adv	(e) [X] An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);			
(f) [] An employee bene	efit plan or endowment fund in a	ccordance with §240.13d-1(b)(1)(ii)(F);	
(g) [] A parent holding of	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);			
(h) [] A savings associa	tions as defined in Section 3(b) c	of the Federal Deposit Insuran	ce Act (12 U.S.C. 1813);	
(i) [] A church plan tha of 1940 (15 U.S.C		of an investment company un	nder section 3(c)(14) of the Investment Company Act	
(j) [] Group, in accorda	nce with §240.13d-1(b)(1)(ii)(J).			

CUSIP No. 00202J203	13G/A	Page 5 of 7 Pages
---------------------	-------	-------------------

Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

Amount beneficially owned: (a)

The Reporting Persons beneficially own 31,504,199* shares of Common Stock held by a private investment fund (the "Fund") to which Perceptive Advisors LLC serves as the investment manager, which includes 18,352,404 shares of Common Stock and 13,151,795 shares underlying Common Stock purchase warrants held by the Reporting Persons. Mr. Edelman is the managing member of Perceptive Advisors LLC.

Percent of class: (b)

The beneficial ownership of 9.99% is based on the sum of 302,205,555 shares of Common Stock as reflected on the Issuer's 10-Q on November 5, 2012 and the number of Warrants owned by the Reporting Persons.*

*Excludes 181,538.5 shares underlying Common Stock purchase warrants held by the Reporting Persons. These warrants are not presently exercisable due to an exercisability limitation included in the Warrant which provides that the warrants are not exercisable (i) while the holder is a beneficial owner of over 9.99 % of the shares of the Issuer or (ii) to the extent that such exercise would cause the holder's beneficial ownership to exceed 9.99%.

- (c) Number of shares as to which the person has:
 - (i) Sole power to vote or to direct the vote:

0

0

(ii) Shared power to vote or to direct the vote:

31,504,199

(iii) Sole power to dispose or to direct the disposition of:

31,504,199

(iv) Shared power to dispose or to direct the disposition of:

Item 5 Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: £.

Item 6 Ownership of More Than Five Percent on Behalf of Another Person

The Fund described in Item 4 has the right to receive or the power to direct the receipt of dividends from, or the proceeds from, the sale of the securities held in its account. Filing of this statement by the Reporting Persons shall not be deemed an admission that they beneficially own the securities reported herein. The Reporting Persons expressly disclaim beneficial ownership of all securities reported herein.

Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not applicable.

CUSIP No. 00202J203 13G/A Page 6 of 7 Pages

Item 8. Identification and Classification of Members of the Group.

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certification

(a) The following certification shall be included if the statement is filed pursuant to §240.13d-1(b):

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. S

CUSIP No. 00202J203	13G/A	Page 7 of 7 Pages
	SIGNATURE	
After reasonable inquiry and to the best of correct.	my knowledge and belief, I certify that the inform	nation set forth in this statement is true, complete and
	<u>February 14, 2013</u> Date	
	PERCEPTIVE ADVISO	DRS LLC
	/s/ Joseph Edelman Signature	
	Joseph Edelman/Managi Name/Title	ing Member
	<u>February 14, 2013</u> Date	

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

/s/ Joseph Edelman

Joseph Edelman Name/Title

Signature

NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties for whom copies are to be sent.

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)